<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505984</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001100</org_study_id>
    <secondary_id>224421</secondary_id>
    <secondary_id>225686</secondary_id>
    <secondary_id>1R21HD090396-01A1</secondary_id>
    <nct_id>NCT02505984</nct_id>
  </id_info>
  <brief_title>Preventing Postpartum Depression With Intranasal Oxytocin</brief_title>
  <acronym>IN-OXT</acronym>
  <official_title>Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a new treatment for preventing childbirth-related mental&#xD;
      illness in postpartum mothers. The treatment is aimed at enhancing maternal bonding, reducing&#xD;
      postpartum depression (PPD) and anxiety in mothers at risk, and promoting child development.&#xD;
      To this end, the investigators will test the clinical utility of intranasal (IN) oxytocin&#xD;
      (OXT) administered to mothers during the first postpartum days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum depression (PPD) is a debilitating disorder which imposes a threat to mother and&#xD;
      infant health. An estimated 600,000 American women suffer from PPD annually, making it one of&#xD;
      the most frequent complications of pregnancy. Available secondary preventive interventions&#xD;
      are often ineffective, which calls for identifying novel means for prevention. Impaired&#xD;
      mother-infant bonding is a hallmark of PPD. Depressed mothers may have difficulties&#xD;
      developing maternal feelings and providing sensitive care. In turn, impaired bonding may&#xD;
      worsen mother's depression. Conventional pharmacotherapy does not help with bonding&#xD;
      impairment.&#xD;
&#xD;
      This study will attempt to fill in the current gap in effective preventive interventions for&#xD;
      pregnant mothers at risk. Evidence in postpartum mothers indicates that high peripartum OXT&#xD;
      levels are associated with enhanced maternal behavior and low levels with depression. Data&#xD;
      also indicates that in depressed mothers, OXT levels may decrease during the first days&#xD;
      following childbirth rather than increase as is the norm. Therefore, the investigators will&#xD;
      test the therapeutic effects of OXT in women at risk for PPD. It is hypothesized that&#xD;
      administration of IN-OXT (total daily dose 48 IU) over the course of four days from as early&#xD;
      as day one postpartum in comparison to placebo will 1) enhance mother-infant bonding, 2)&#xD;
      reduce depressive and anxiety symptoms at 5 days postpartum, and 3) facilitate child&#xD;
      development.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment effect on mother-infant bonding</measure>
    <time_frame>Day 5 postpartum and 2 months postpartum</time_frame>
    <description>Day 5 postpartum:&#xD;
Self-report assessment of maternal bonding&#xD;
2 months postpartum: Quantitative observational assessment of mother-infant bonding and repeat of self-reports</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in depression symptoms</measure>
    <time_frame>Baseline and day 5 postpartum</time_frame>
    <description>Self-reported severity of depression symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety symptoms</measure>
    <time_frame>Baseline and day 5 postpartum</time_frame>
    <description>Self-reported severity of anxiety symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child development</measure>
    <time_frame>2 months postpartum</time_frame>
    <description>Quantitative observational assessment of infant socio-emotional, cognitive, and motor development</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Depression, Postpartum</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sub-group of participants receiving oxytocin nasal spray (Syntocinon)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sub-group of participants receiving placebo nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Study participants will be randomized to a placebo or drug group.</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study participants will be randomized to a placebo or drug group.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Salt solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Third-trimester pregnant women being followed at the MGH Obstetrics Program&#xD;
&#xD;
          -  At risk of postpartum depression (PPD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to participate in regular prenatal check-ups&#xD;
&#xD;
          -  Current diagnosis DSM-5 mental disorder pertaining to psychosis or substance abuse&#xD;
&#xD;
          -  Suicidality&#xD;
&#xD;
          -  Obstetric complication (e.g., preeclampsia, excessive hemorrhaging)&#xD;
&#xD;
          -  Use of potentially confounding or interacting medications&#xD;
&#xD;
          -  Complicating pediatric medical condition in the newborn.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Dekel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hosptial</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hosptial</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mah BL, Bakermans-Kranenburg MJ, Van IJzendoorn MH, Smith R. Oxytocin promotes protective behavior in depressed mothers: a pilot study with the enthusiastic stranger paradigm. Depress Anxiety. 2015 Feb;32(2):76-81. doi: 10.1002/da.22245. Epub 2014 Feb 12.</citation>
    <PMID>24523054</PMID>
  </reference>
  <reference>
    <citation>Skrundz M, Bolten M, Nast I, Hellhammer DH, Meinlschmidt G. Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology. 2011 Aug;36(9):1886-93. doi: 10.1038/npp.2011.74. Epub 2011 May 11.</citation>
    <PMID>21562482</PMID>
  </reference>
  <reference>
    <citation>Fewtrell MS, Loh KL, Blake A, Ridout DA, Hawdon J. Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants. Arch Dis Child Fetal Neonatal Ed. 2006 May;91(3):F169-74. Epub 2005 Oct 13.</citation>
    <PMID>16223754</PMID>
  </reference>
  <reference>
    <citation>Riem MM, Bakermans-Kranenburg MJ, Pieper S, Tops M, Boksem MA, Vermeiren RR, van Ijzendoorn MH, Rombouts SA. Oxytocin modulates amygdala, insula, and inferior frontal gyrus responses to infant crying: a randomized controlled trial. Biol Psychiatry. 2011 Aug 1;70(3):291-7. doi: 10.1016/j.biopsych.2011.02.006. Epub 2011 Apr 5. Erratum in: Biol Psychiatry. 2012 Apr 1;71(7):660.</citation>
    <PMID>21470595</PMID>
  </reference>
  <reference>
    <citation>Jobst A, Krause D, Maiwald C, H채rtl K, Myint AM, K채stner R, Obermeier M, Padberg F, Br체cklmeier B, Weidinger E, Kieper S, Schwarz M, Zill P, M체ller N. Oxytocin course over pregnancy and postpartum period and the association with postpartum depressive symptoms. Arch Womens Ment Health. 2016 Aug;19(4):571-9. doi: 10.1007/s00737-016-0644-2. Epub 2016 Jun 20.</citation>
    <PMID>27320943</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 19, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Sharon Dekel, PhD</investigator_full_name>
    <investigator_title>Assistant Professor in Psychology</investigator_title>
  </responsible_party>
  <keyword>oxytocin, bonding</keyword>
  <keyword>child development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

